Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 9/20 | 0.38 |
| ▸ | NMT2 | O60551 | 8/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.36 |
| ▸ | CD40 | P25942 | 2/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19776913 | 0.90 | NMT2 (0.39) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL20349812 | 0.90 | NMT2 (0.39) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL20287715 | 0.88 | NMT2 (0.35) | NMT1NMT2CD40OPRL1 | |
| SCHEMBL21972921 | 0.87 | NMT1 (0.40) | NMT1NMT2TLR2ROCK2CD40 | |
| SCHEMBL17722906 | 0.81 | NMT1 (0.48) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL17860183 | 0.81 | NMT2 (0.40) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL18909077 | 0.80 | NMT1 (0.48) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL23436462 | 0.79 | NMT1 (0.46) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL20889000 | 0.79 | NMT1 (0.46) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL22349913 | 0.79 | HRH1 (0.38) | NMT1NMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11123439-B2 | Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-09-21 | — | — | US | disclosed |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11123439-B2 | Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups | KIFC1, KIF2C, KIF5B | NMT1 2582/4885NMT2 2936/4885TLR2 4851/4885 |
| US-20180169256-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | KIFC1, KIF2C, KIF5B | NMT1 2582/4885NMT2 2936/4885TLR2 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.